Correlation of population pharmacokinetics and dynamics of commonly used aminoglycoside amikacin with snp’s (single neucleotide polymorphism)

Amikacin is an Aminoglycoside group of antibiotic, it is a semi synthetic derivative prepared from Kanamycin A by acylation of the 1-amino group of the 2-deoxystreptamine moiety with 2-hydroxy-4-aminobutyric acid. Amikacin is an antibiotic used for a number of bacterial infections. Amikacin have the potential to produce reversible and irreversible vestibular, cochlear, and renal toxicity. Cytochrome P4503A4 (abbreviated CYP3A4), is an important enzyme in the body, mainly found in the liver and in the intestine. In this study, we have tried to evaluate if there is any relation between high serum Amikacin level and presence of CYP3A4*22 in an individual. Study population was patients admitted in Medicine and Paediatrics department receiving Amikacin as antimicrobial of all ages and both sexes. Each patient were observed for any kind of adverse drug reaction during the period of antimicrobial therapy with Amikacin. Therapeutic drug monitoring of Amikacin was done for the patients who had any complain during that period. In the last step, CYP3A4*22 status was estimated for those patients with ADRs to see whether there is any correlation of the SNP (CYP3A4*22) with high serum Amikacin level. Apparatus used were High Performance Liquid Chromatography and Real Time PCR. So from the observations, it can be concluded that high serum Amikacin level has a correlation with adverse reactions of Amikacin. But, as it is seen that CYP3A4*22 is present in both group of patients ie. High and normal serum Amikacin level. It can be concluded that CYP3A4*22 has no correlation with high serum level of Amikacin.